Bristol Myers Squibb’s Augtyro Granted FDA Priority Review for NTRK-Positive Locally Advanced, Metastatic Solid Tumors

Augtyro is a potential best-in-class tyrosine kinase inhibitor that targets ROS1- or NTRK-positive locally advanced or metastatic solid tumors.